Modular Medical (Modular Medical (MODD)) just flipped the switch from development to commercial reality. The company announced Wednesday that its Pivot tubeless insulin patch pump is now available in the U.S., marking the first time real patients will actually use the device. The FDA gave the green light back in June, and now the rubber meets the road.
The Pivot is only the second fully electronic, tubeless insulin pump currently available in the U.S. That's a pretty exclusive club. The device has a removable two-part design, a 3-milliliter reservoir, and an interface that's supposed to be intuitive enough to convince people who've been scared off by pump complexity. It's wearable, supports showering and sports, and doesn't need battery recharging while maintaining connectivity and clinical accuracy.
Modular Medical's pitch is that its patented technology eliminates the tradeoff between complexity and effectiveness. The company wants to make advanced insulin delivery systems more affordable and easier to learn. That's a big deal because a huge chunk of the diabetes market has been sitting on the sidelines.
The company is specifically targeting what it calls "almost-pumpers" — adults with diabetes who rely on multiple daily injections but haven't switched to a pump because of cost, complexity, or usability concerns. Modular Medical estimates that roughly 70% of insulin-dependent adults are still on daily injections. That's a massive, multibillion-dollar opportunity in the diabetes technology market.
The commercial launch won't happen all at once. Modular Medical is taking a phased approach, starting with select high-volume endocrinology practices and then expanding to multiple metropolitan markets by late 2026. It's a measured rollout, but the company is now officially a commercial-stage medical device company.
Investors seem to like the news. Modular Medical shares were up 7.95% in premarket trading Wednesday, sitting at $4.63.
